Efficient in vitro oxaliplatin delivery with functionalized single-walled carbon nanotube for enhanced colon cancer treatment

Future Journal of Pharmaceutical Sciences

Table 1 In vitro cytotoxicity of oxaliplatin and FA-CHI- FSWCNT-OXA against COLO320DM

Compound	% inhibition	% viability
In vitro cytotoxicity of oxaliplatin and FA-CHI- FSWCNT-OXA against COLO320DM
MTT assay
Oxaliplatin plain	66.58 ± 0.38	33.36 ± 0.74
FA-CHI-FSWCNT-OXA	92.36 ± 0.94***	7.2333 ± 0.64***
SRB assay
Oxaliplatin plain	76.69 ± 0.52	23.3766 ± 0.44
FA-CHI-FSWCNT-OXA	91.22 ± 0.90***	9.2566 ± 0.74***
In vitro cytotoxicity of oxaliplatin and FA-CHI- FSWCNT-OXA against HT29
MTT assay
Oxaliplatin plain	76.34 ± 0.95	23.70 ± 0.74
FA-CHI- FSWCNT-OXA	94.14 ± 1.12***	6.35 ± 0.37***
SRB assay
Oxaliplatin plain	72.78 ± 0.35	25.44 ± 1.04
FA-CHI- FSWCNT-OXA	87.51 ± 1.10***	11.64 ± 0.86***

All values are expressed as the mean ± the standard deviation (n = 3). The results are exposed as the mean values ± SEM. ***P < 0.001, ns—not significant when compared to respective control values by Student’s t test